

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.

[Haiman CA](#), [Chen GK](#), [Vachon CM](#), [Canzian F](#), [Dunning A](#), [Millikan RC](#), [Wang X](#), [Ademuyiwa F](#), [Ahmed S](#), [Ambrosone CB](#), [Baglietto L](#), [Balleine R](#), [Bandera EV](#), [Beckmann MW](#), [Berg CD](#), [Bernstein L](#), [Blomqvist C](#), [Blot WJ](#), [Brauch H](#), [Buring JE](#), [Carey LA](#), [Carpenter JE](#), [Chang-Claude J](#), [Chanock SJ](#), [Chasman DI](#), [Clarke CL](#), [Cox A](#), [Cross SS](#), [Deming SL](#), [Diasio RB](#), [Dimopoulos AM](#), [Driver WR](#), [Dünnebier T](#), [Durcan L](#), [Eccles D](#), [Edlund CK](#), [Ekici AB](#), [Fasching PA](#), [Feigelson HS](#), [Flesch-Janys D](#), [Fostira F](#), [Fürsti A](#), [Fountzilas G](#), [Gerty SM](#); Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, [Giles GG](#), [Godwin AK](#), [Goodfellow P](#), [Graham N](#), [Greco D](#), [Hamann U](#), [Hankinson SE](#), [Hartmann A](#), [Hein R](#), [Heinz J](#), [Holbrook A](#), [Hoover RN](#), [Hu JJ](#), [Hunter DJ](#), [Ingles SA](#), [Irwanto A](#), [Ivanovich J](#), [John EM](#), [Johnson N](#), [Jukkola-Vuorinen A](#), [Kaaks R](#), [Ko YD](#), [Kolonel LN](#), [Konstantopoulou I](#), [Kosma VM](#), [Kulkarni S](#), [Lambrechts D](#), [Lee AM](#), [Marchand LL](#), [Lesnick T](#), [Liu J](#), [Lindstrom S](#), [Mannermaa A](#), [Margolin S](#), [Martin NG](#), [Miron P](#), [Montgomery GW](#), [Nevanlinna H](#), [Nickels S](#), [Nyante S](#), [Olswold C](#), [Palmer J](#), [Pathak H](#), [Pectasides D](#), [Perou CM](#), [Peto J](#), [Pharoah PD](#), [Pooler LC](#), [Press MF](#), [Pylkäs K](#), [Rebbeck TR](#), [Rodriguez-Gil JL](#), [Rosenberg L](#), [Ross E](#), [Rüdiger T](#), [Silva Idos S](#), [Sawyer E](#), [Schmidt MK](#), [Schulz-Wendtland R](#), [Schumacher F](#), [Severi G](#), [Sheng X](#), [Signorello LB](#), [Sinn HP](#), [Stevens KN](#), [Southee MC](#), [Tapper WJ](#), [Tomlinson I](#), [Hogervorst FB](#), [Wauters E](#), [Weaver J](#), [Wildiers H](#), [Winqvist R](#), [Van Den Berg D](#), [Wan P](#), [Xia LY](#), [Yannoukakos D](#), [Zheng W](#), [Ziegler RG](#), [Siddiq A](#), [Slager SL](#), [Stram DO](#), [Easton D](#), [Kraft P](#), [Henderson BE](#), [Couch FJ](#).

Source

Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, USA. haiman@usc.edu

Abstract

Estrogen receptor (ER)-negative breast cancer shows a higher incidence in women of African ancestry compared to women of European ancestry. In search of common risk alleles for ER-negative breast cancer, we combined genome-wide association study (GWAS) data from women of African ancestry (1,004 ER-negative cases and 2,745 controls) and European ancestry (1,718 ER-negative cases and 3,670 controls), with replication testing conducted in an additional 2,292 ER-negative cases and 16,901 controls of European ancestry. We identified a common risk variant for ER-negative breast cancer at the TERT-CLPTM1L locus on chromosome 5p15 (rs10069690: per-allele odds ratio (OR) = 1.18 per allele, $P = 1.0 \times 10(-10)$). The variant was also significantly associated with triple-negative (ER-negative, progesterone receptor (PR)-negative and human epidermal growth factor-2 (HER2)-negative) breast cancer (OR = 1.25, $P = 1.1 \times 10(-9)$), particularly in younger women (<50 years of age) (OR = 1.48, $P = 1.9 \times 10(-9)$). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations.